JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Heparanase mRNA and Protein Expression Correlates with Clinicopathologic Features of Gastric Cancer Patients: a Meta-analysis
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Heparanase mRNA and Protein Expression Correlates with Clinicopathologic Features of Gastric Cancer Patients: a Meta-analysis
Li, Hai-Long; Gu, Jing; Wu, Jian-Jun; Ma, Chun-Lin; Yang, Ya-Li; Wang, Hu-Ping; Wang, Jing; Wang, Yong; Chen, Che; Wu, Hong-Yan;
  PDF(new window)
 Abstract
Background: Heparanase is believed to be involved in gastric carcinogenesis. However, the clinicopathologic features of gastric cancer with high heparanase expression remain unclear. Aim : The purpose of this study was to comprehensively and quantitatively summarize available evidence for the use of heparanase mRNA and protein expression to evaluate the clinicopathological associations in gastric cancer in Asian patients by meta-analysis. Materials and Methods: Relevant articles listed in MEDLINE, CNKI and the Cochrane Library databases up to MARCH 2015 were searched by use of several keywords in electronic databases. A meta-analysis was performed to clarify the impact of heparanase mRNA and protein on clinicopathological parameters in gastric cancer. Combined ORs with 95%CIs were calculated by Revman 5.0, and publication bias testing was performed by stata12.0. Results: A total of 27 studies which included 3,891 gastric cancer patients were combined in the final analysis. When stratifying the studies by the pathological variables of heparanase mRNA expression, the depth of invasion (633 patients) (OR
 Keywords
Gastric cancer;heparanase;clinicopathologic features;meta-analysis;
 Language
English
 Cited by
1.
Oleuropein represses the radiation resistance of ovarian cancer by inhibiting hypoxia and microRNA-299-targetted heparanase expression, Food Funct., 2017, 8, 8, 2857  crossref(new windwow)
 References
1.
Cai YG, Fang DC, Yang SM, et al (2004). [Increased expression of heparanase mRNA is correlated with metastasis of gastric carcinoma and is probably correlated with c-met protein]. Zhonghua Yi Xue Za Zhi, 84, 974-8.

2.
Chen JQ, Zhan WH, He YL, et al (2004a). Expression of heparanase gene, CD44v6, MMP-7 and nm23 protein and their relationship with the invasion and metastasis of gastric carcinomas. World J Gastroenterol, 10, 776-82. crossref(new window)

3.
Chen JQ, Zhan WH, He YL, et al (2004b). [Relationship between heparanase mRNA expression in human gastric cancer and its clinicopathological features]. Zhonghua Zhong Liu Za Zhi, 26, 609-11.

4.
Cheng C, Lu X, Wang G, et al (2010). Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS, 118, 855-63. crossref(new window)

5.
Han Y, Xue XF, Shen HG, et al (2014). Prognostic significance of Beclin-1 expression in colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 4583-7. crossref(new window)

6.
Inoue H, Mimori K, Utsunomiya T, et al (2001). Heparanase expression in clinical digestive malignancies. Oncol Rep, 8, 539-42.

7.
Liu WJ, Tan XH, Guo BP, et al (2013). Associations between RASSF1A promoter methylation and NSCLC: a metaanalysis of published data. Asian Pac J Cancer Prev, 14, 3719-24. crossref(new window)

8.
Liu Y, Lv DL, Duan JJ, et al (2014). ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and metaanalysis. BMC Cancer, 14, 444. crossref(new window)

9.
Masola V, Secchi MF, Gambaro G, et al (2014). Heparanase as a target in cancer therapy. Curr Cancer Drug Targets, 14, 286-93. crossref(new window)

10.
McShane LM, Altman DG, Sauerbrei W, et al (2006). REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat, 100, 229-35. crossref(new window)

11.
Nadir Y, Brenner B (2014). Heparanase multiple effects in cancer. Thromb Res, 133 Suppl 2, 90-4.

12.
Naomoto Y, Takaoka M, Okawa T, et al (2005). The role of heparanase in gastrointestinal cancer (Review). Oncol Rep, 14, 3-8.

13.
Pisano C, Vlodavsky I, Ilan N, et al (2014). The potential of heparanase as a therapeutic target in cancer. Biochem Pharmacol, 89, 12-9. crossref(new window)

14.
QIN S-y, JIANG H-x, LI X (2007). Significance of bFGF, FGFR-2 and Hpa expression in gastric precancerous lesions and gastric carcinoma tissues. Chinese J Practical Internal Med, 17, 025.

15.
REN X-l, ZHU R-z, WANG L-j (2003). Clinicopathological significance of heparanase mRNA expression in gastric carcinoma. Chinese J Exp Surg, 9, 006.

16.
Takaoka M, Naomoto Y, Ohkawa T, et al (2003). Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab Invest, 83, 613-22. crossref(new window)

17.
Tang W, Nakamura Y, Tsujimoto M, et al (2002). Heparanase: a key enzyme in invasion and metastasis of gastric carcinoma. Mod Pathol, 15, 593-8. crossref(new window)

18.
Wang Z, Xu H, Jiang L, et al (2005). Positive association of heparanase expression with tumor invasion and lymphatic metastasis in gastric carcinoma. Mod Pathol, 18, 205-11. crossref(new window)

19.
Wu BW, Li DF, Ke ZF, et al (2010). Expression characteristics of heparanase in colon carcinoma and its close relationship with cyclooxygenase-2 and angiogenesis. Hepatogastroenterol, 57, 1510-4.

20.
Xi Y, Zhang Y, Qi YJ, et al (2009). Expression of heparanase and CD105 in stomach neoplasm and its correlation. J Henan University, 3, 010.

21.
Zhang J, Yang J, Han X, et al (2012). Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy. Oncol Lett, 4, 178-82. crossref(new window)

22.
Zhang X, Xu S, Tan Q, et al (2013). High expression of heparanase-2 is an independent prognostic parameter for favorable survival in gastric cancer patients. Cancer Epidemiol, 37, 1010-3. crossref(new window)

23.
Zheng L, Jiang G, Mei H, et al (2010). Small RNA interferencemediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer, 10, 33. crossref(new window)

24.
Zheng L, Weng M, Qi M, et al (2012). Aberrant expression of intelectin-1 in gastric cancer: its relationship with clinicopathological features and prognosis. J Cancer Res Clin Oncol, 138, 163-72. crossref(new window)

25.
Zheng LD, Jiang GS, Pu JR, et al (2009). Stable knockdown of heparanase expression in gastric cancer cells in vitro. World J Gastroenterol, 15, 5442-8. crossref(new window)

26.
Cai YG, Fang DC, Yang ShM, et al (2004). The significance of the expression of heparanase mRNA in gastric cancer tissues. J Fourth Military Med University, 909-11.

27.
Chen Bo (2009). Expressions of heparanase and matrix metalloproteinase-9 in gastric cancer and its clinical significance. J Hainan Med College, 852-4

28.
Huang ZHQ, Liu SH, Chen SL, et al (2008). The study of HPA, bFGF and FGFR-2 expressions in gastric cancer tissue. J Modern Chinese Western Integrated Med. 3565, 6-75.

29.
Jiang WH, Zhu XM, Yang ZHP, et al (2011). The expression of heparanase in gastric cancer tissue with its clinical pathological features. Chinese J Gerontol, 3262-3.

30.
Li Tao, QJ (2012). The expression and significance of integrin alpha 5 beta 1 and heparanase in gastric carcinoma. Guangdong Med. 2974-6.

31.
Liang H, Zhang L, Zhang Xu (2009). The expression and clinical significance of HPA in gastric cancer tissues. Health Vocational Educat, 102-3.

32.
Liu Y, Yang HG, Zuo LF (2007). The expression of heparanase in gastric cancer and DNA content quantitative research by flow cytometry. J Med Res, 40-3.

33.
Liu ZH, An ZhQ, Li EJ, et al (2004). The expressions of heparanase, bFGF fibroblast growth factor expression in gastric cancer with their effects on angiogenesis and tumor progression. Sichuan J Physiological Sci 106-8.

34.
Ma XM, Sun Q, Ren MJ, et al (2007). The expressions of heparanase and NF kappa B in gastric cancer and with the clinical pathological features and vascular formation. J China Histochemistry Cytochemistry, 12-8.

35.
Qi YQ, Si JL, Li WL, et al (2010). The expressions of Syndecan-1 and HPA-1 mRNA in gastric cancer tissue and its relationship with invasion and metastasis of gastric cancer. Chinese J Cancer, 110-5.

36.
Ru GQ, Zhao ZHS, Tang QL, et al (2006). The mRNA expressions of Syndecan-1 and heparanase in gastric cancer and its relationship with metastasis and prognosis of gastric cancer. Chinese J Surg, 1062-4.

37.
Su N, Chen B, Chen JZH, et al (2009). The expression of heparanase in gastric cancer and hepatocellular carcinoma and its clinical significance. J Practical Med, 1207-9.

38.
Sun YS, Ye ZY, a randomised (2005). The expression of heparanase protein in gastric cancer and its clinical significance. Zhejiang Med J, 644, 5-9.

39.
Wang ZhH, Wang YH, Jiang FT, et al (2008). The expressions and significances of heparanase in gastric cancer, paracancerous tissues and normal gastric tissue. Modern Med Oncol, 1953-5.

40.
Zhang L, Zhang X, Yang AJ, et al (2009). The expressions and significances of HPA and HIF-1 in gastric cancer. Shandong J Med Pharmcol, 89-90.

41.
Zheng ZHC, Wang SHB, Xu HM (2004). The expressions of heparanase and bFGF in gastric cancer and its relationship with invasion and metastasis of gastric cancer. Chinese J Clin Oncol, 31, 4-8.